The two-year study showed that by using Applied NeuroSolutions’ test, which measures the amount of an abnormal protein, called p-tau in conjunction with current methods to diagnose Alzheimer’s, scientists were able to accurately detect the disorder in approximately 90% of cases.
Doctors currently utilize memory tests and magnetic resonance imaging (MRI) to diagnose Alzheimer’s, which is often misdiagnosed and confused with other neurological disorders, including depression and Parkinson’s disease.
“This study makes clear the important role that our test can play in definitively and accurately detecting Alzheimer’s, especially early on in the progression of the disease,” commented Dr John DeBernardis, president and CEO of Applied NeuroSolutions.